In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. In this webinar, Thermo Fisher senior executives Franco Negron and Leon Wyszkowski provide an inside view of how Pharma Services is redefining outsourced biopharmaceutical services.

Attendees who are interested in M&A, drug development, and clinical outsourcing will gain the following insights from the webinar:

  • The status of the integration of Patheon into Thermo Fisher Scientific.
  • An introduction to Thermo Fisher’s Pharma Services.
  • The unified operational and business strategy established to deliver manufacturing and clinical services to clients.
  • A forward-looking view of the evolution of outsourced pharmaceutical services.
  • An open question and answer segment.


Featured Speakers

Franco Negron

President, Pharma Services Commercial Operations
Thermo Fisher Scientific

Franco joined Thermo Fisher through the acquisition of Patheon Pharmaceuticals back in 2017, and immediately took on a critical role as President of Commercial Operations for the Pharma Services Group. His experience in the pharmaceutical industry spans more than 20 years, and he has worked at multiple top tier companies including VP of Manufacturing & Supply at Valeant Pharmaceuticals, Global VP in Novartis’ Consumer Health, and Site GM at McNeil Consumer. Franco began his 8-year tenure with Patheon as VP and GM of Operations for all the Patheon sites in Puerto Rico. Franco holds a Bachelor of Science in Electrical Engineering from the University of Puerto Rico Mayaguez and certificates from both Kellogg School of Management and the University of Chicago. 

Leon Wyszkowski

President, Clinical Trials Division
Thermo Fisher Scientific

Leon has worked in drug development for over 22 years with extensive experience in operations, client services and supply chain logistics. Leon joined Thermo Fisher Scientific in 2006 as the BioPharma Services Division General Manager of the Bristol facility. He was promoted to Vice President and General Manager of the Allentown site in 2009. During that time, Leon led contract negotiations to form a strategic partnership with Eli Lilly. This agreement included a first-in- the-industry service line approach to manage both their internal manufacturing and packaging operations. Leon was again promoted in 2010 to VP & GM Clinical Services in North America and his role expanded further in 2014 to VP, Clinical Services


Register now for this webinar